Researchers find new type of antibiotic against the cholera bacteria

Just as hurricanes in the Gulf states and Guatemala have raised the risks of cholera outbreaks, researchers at Harvard Medical School have identified a new type of antibiotic against the cholera bacteria.

While traditional antibiotics kill bacteria outright by interfering with processes essential for their survival, the new agent blocks production of bacterial proteins that cause the severe diarrhea associated with Vibrio cholerae infection.

"What we have done is made a custom, organism-specific antibiotic against Vibrio cholerae," said John Mekalanos, the Adele Lehman professor of microbiology and molecular genetics at HMS and the senior author on a report of the work appearing in the online edition of Science.

Using a high-throughput screen of 50,000 small molecule candidate compounds, Mekalanos and lead author Deborah Hung identified several that turned off the expression of virulence proteins, factors that help the bacteria invade its human host and cause disease. They then showed that the most promising compound prevented cholera bacteria from setting up an infection when introduced into the digestive tract of mice.

Since most disease-causing organisms use elaborate virulence factors such as toxins to do their damage, the new approach should be widely applicable. "There is no reason our results cannot be replicated for a number of other important pathogens," Mekalanos said.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
HNL Dimer as a promising biomarker for monitoring antibiotic treatment in sepsis